Literature DB >> 1643615

Hodgkin disease in the elderly. A registry-based analysis.

F L Erdkamp1, W P Breed, L J Bosch, J T Wijnen, G B Blijham.   

Abstract

Limited data regarding the cause of the age-related decrease in survival times in patients with Hodgkin disease are available. In a retrospective study of a nonselected population of patients with Hodgkin disease, the authors evaluated which factors contributed to the age-related prognostic effect in this disease. The survival curves of 182 patients were compared, and survival time was found to decrease markedly after the age of 50 years. Differences in disease characteristics between older and younger patients were small and not statistically significant. Significantly fewer older patients received adequate treatment (34% versus 2%), and they were less likely to have complete disease remission (61% versus 90%). However, the relapse-free survival time of patients with complete disease remission was not significantly different from that of younger patients, 50% of all patients being free of disease after 10 years. Intercurrent disease did not appear to be responsible for decreased survival times in the elderly (32% versus 26%). The authors conclude that the inability to give adequate treatment seems to be the major determinant of the poorer overall survival time of older patients with Hodgkin disease.

Entities:  

Mesh:

Year:  1992        PMID: 1643615     DOI: 10.1002/1097-0142(19920815)70:4<830::aid-cncr2820700418>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Management of older Hodgkin lymphoma patients.

Authors:  Andrew M Evens; Jordan Carter; Kah Poh Loh; Kevin A David
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.

Authors:  Teresa V Halbsguth; Boris Böll; Peter Borchmann; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

3.  ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years.

Authors:  Bosko M Andjelic; Biljana S Mihaljevic; Ljubomir R Jakovic
Journal:  Pathol Oncol Res       Date:  2012-01-11       Impact factor: 3.201

4.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

5.  Clinical and Epidemiological Profile of Elderly Hodgkin's Lymphoma in India.

Authors:  Manish Sharma; Pankaj Goyal; Rajesh Ranjan; Udip Maheshwari; Dinesh Bhurani; Chaturbhuj Aggarwal; Venkata Pradeep Babu Koyyala; Parveen Jain; Narendra Agrawal; Rayaz Ahmed
Journal:  Cureus       Date:  2022-07-15

6.  A case-control study of Hodgkin's disease and pregnancy.

Authors:  M Zwitter; M P Zakelj; K Kosmelj
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

Review 7.  Immunosenescence and lymphomagenesis.

Authors:  Salvatrice Mancuso; Melania Carlisi; Marco Santoro; Mariasanta Napolitano; Simona Raso; Sergio Siragusa
Journal:  Immun Ageing       Date:  2018-09-21       Impact factor: 6.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.